# Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group

> **NCT01901133** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 33 (actual)

## Conditions studied

- Pharmacokinetics of MDV3100
- Healthy Subjects
- Kidney Diseases

## Interventions

- **DRUG:** MDV3100

## Key facts

- **NCT ID:** NCT01901133
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2014-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01901133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01901133, "Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01901133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*